NCT03582618


A Phase 2, Open-Label Study with Orally Administered CVM-1118 and Sorafenib in Subjects with Advanced Hepatocellular Carcinoma (TaiRx)



Adult


The purpose of this study is to test the effectiveness, safety, and tolerability of an investigational drug combination of CVM-1118 and sorafenib in participants with advanced HCC.

See full details